Within the last decade, the discovery of red wine as a
proponent for increased cardiovascular health has been prominent in
science-related media . The compound in question is called
“Resveratrol,” and its ability to lead the consumer to a longer, healthier life
has been controversial due to lack of reproducible results of Dr. David
Sinclair, molecular biologist at Harvard Medical School and founder of Sirtis
(SIRT research).
Upon clarification by more recent research, Resveratrol is
thought to boost activity of the enzyme SIRT1, in conjunction with a bulky
hydrophobic amino acid residue, to de-acetylate proteins involved in aging and
metabolism. Resveratrol acts on a wide variety of proteins, and the full extents
of its effects are still to be determined.
More recently, researchers have been exploring the use of
resveratrol in other areas of health, namely in the reduction of ocular hypertension
(OHTN). Systemic, topical, periocular, or intravitreal use of steroids (as
therapy for ailments of the eye) can lead to onset of OHTN, which can then lead
to glaucoma. Current therapies are not effective in reducing intra-occular
pressure (IOP) and often cause negative effects systemically and locally, so there
has been a push to develop better treatment options for patients suffering from
OHTN. A recent study has successfully used resveratrol
to reduce IOP in rats.
The experiment was two-part: IOP reduction by resveratrol in
normotensive rats, and IOP reduction by resveratrol in steroid-induced OHTN
rats. Both the normotensive and OHTN groups tested a vehicle (control) solution
in one eye. A vehicle solution contains everything that the drug solution
contains, except the drug; in this case, the vehicle contained 3% polyvinylpyrrole
(PVP), which was used to dissolve the resveratrol in the drug solution. The
drug solution contained trans-resveratrol, which is the more biologically
active conformation of the compound (as compared to cis-resveratrol).
The study showed that application of trans-resveratrol was
effective in reducing IOP in both the normotensive and steroid-induced OHTN
rats. In both sets of rats, 0.2% trans-resveratrol achieved peak IOP reduction:
15.1% reduction in the normotensive rats and 25.5% reduction in the OHTN rats.
This study lends possibility to new treatments for OHTN, but also to untapped
uses of resveratrol in the eye. I will actually be exploring one of these uses in
an Opthalmology lab at the Anschutz Medical Campus—I’ll be testing the effect
of resveratrol on dry eye in a murine model.